Suppr超能文献

三步小麦口服免疫疗法用于重度小麦过敏儿童的可行性研究

Feasibility of a 3-step protocol of wheat oral immunotherapy in children with severe wheat allergy.

作者信息

Wongteerayanee Chulamanee, Tanticharoenwiwat Pattara, Rutrakool Nuntanut, Senavonge Anchalee, Jeekungwal Nivat, Pacharn Punchama, Vichyanond Pakit

机构信息

Samitivej Allergy Institute (SAI), Samitivej Thonburi Hospital, Bangkok, Thailand.

Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.

出版信息

Asia Pac Allergy. 2020 Oct 20;10(4):e38. doi: 10.5415/apallergy.2020.10.e38. eCollection 2020 Oct.

Abstract

BACKGROUND

Wheat allergy is not an uncommon event among Thai children. Despite strict avoidance, some patients developed reactions after accidental exposure to minute amount of wheat and thus disturbed their quality of life. Wheat oral immunotherapy (OIT) has been reported to be an alternative treatment for such patients.

OBJECTIVE

We designed a new 3-step wheat OIT protocol for treatment of severe wheat allergy in Thai patients. The feasibility of the protocol is evaluated and is reported here in this paper.

METHODS

We retrospectively reviewed medical records of 26 patients who had undergone wheat OIT during a 30-month period. The 3-step protocol consisted of an initial phase of double-blind, placebo-controlled food challenge (DBPCFC) and initiation of OIT, a build-up phase, and a maintenance phase. Patient retention in the protocol was the main outcome for this feasibility study. Adverse effects during OIT were recorded. Correlation between serum specific IgE (SpIgE) to wheat and eliciting dose in phase I was determined.

RESULTS

Fourteen females and 12 males with a median age of 6 years were studied. Their median age when wheat allergy began was 8 months. Median SpIgE to wheat was high (198 kU/L). All patients developed reactions during DBPCFC with 17 of 26 patients had moderate to severe reactions required adrenaline injections. Median of eliciting dose of wheat was exceedingly low, i.e., 20 mg of wheat protein. At the end of the study, 23 of 26 patients (88%) were still in the study. Adverse reactions during the build-up phase was frequent (13 patients, 50%), with adrenaline required in 6 occasions. Six patients reached maintenance phase.

CONCLUSION

The new 3-step wheat OIT protocol was feasible in these highly wheat-sensitized patients. Despite a high retention rate, a high rate of adverse effects was observed both during DBPCFC and build-up phases.

摘要

背景

小麦过敏在泰国儿童中并不罕见。尽管严格避免接触,但一些患者在意外接触微量小麦后仍会出现反应,从而影响他们的生活质量。据报道,小麦口服免疫疗法(OIT)是这类患者的一种替代治疗方法。

目的

我们设计了一种新的三步小麦OIT方案,用于治疗泰国患者的严重小麦过敏。本文评估并报告了该方案的可行性。

方法

我们回顾性分析了26例在30个月期间接受小麦OIT治疗的患者的病历。三步方案包括双盲、安慰剂对照食物激发试验(DBPCFC)和OIT起始的初始阶段、剂量递增阶段和维持阶段。方案中的患者留存率是这项可行性研究的主要结果。记录OIT期间的不良反应。确定血清小麦特异性IgE(SpIgE)与I期激发剂量之间的相关性。

结果

研究对象包括14名女性和12名男性,中位年龄为6岁。他们小麦过敏开始时的中位年龄为8个月。小麦的中位SpIgE较高(198 kU/L)。所有患者在DBPCFC期间均出现反应,26例患者中有17例出现中度至重度反应,需要注射肾上腺素。小麦激发剂量的中位数极低,即20毫克小麦蛋白。研究结束时,26例患者中有23例(88%)仍在研究中。剂量递增阶段的不良反应频繁(13例患者,50%),有6次需要使用肾上腺素。6例患者进入维持阶段。

结论

新的三步小麦OIT方案在这些高度小麦敏感的患者中是可行的。尽管留存率较高,但在DBPCFC和剂量递增阶段均观察到较高的不良反应发生率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/722d/7610086/ba19763bbdf9/apa-10-e38-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验